These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. J Rheumatol; 1998 Dec; 25(12):2331-8. PubMed ID: 9858426 [Abstract] [Full Text] [Related]
3. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists. Zink A, Listing J, Ziemer S, Zeidler H, German Collaborative Arthritis Centres. J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156 [Abstract] [Full Text] [Related]
7. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR. Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132 [Abstract] [Full Text] [Related]
9. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences. Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, Lioté F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loët X, Stratégies Thérapeutiques dans La Polyarthrite RhumatoIde Working Group, Club Rhumatismes et Inflammation, French Society of Rheumatology. Arthritis Rheum; 2009 Apr 15; 61(4):425-34. PubMed ID: 19333993 [Abstract] [Full Text] [Related]
11. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. Criswell LA, Such CL, Yelin EH. J Rheumatol; 1997 Dec 15; 24(12):2283-90. PubMed ID: 9415629 [Abstract] [Full Text] [Related]
12. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. Sokka T, Pincus T. J Rheumatol; 2002 Dec 15; 29(12):2521-4. PubMed ID: 12465145 [Abstract] [Full Text] [Related]
13. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey. Saraux A, Devauchelle-Pensec V, Engerran L, Flipo RM. J Rheumatol; 2006 Jul 15; 33(7):1258-65. PubMed ID: 16783865 [Abstract] [Full Text] [Related]
15. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG. J Rheumatol; 2008 Jun 15; 35(6):979-85. PubMed ID: 18412314 [Abstract] [Full Text] [Related]
16. Survey on the use of methotrexate by pediatric rheumatologists in Canada. Chédeville G, Scuccimarri R, Duffy CM. J Rheumatol; 2007 Apr 15; 34(4):818-22. PubMed ID: 17309120 [Abstract] [Full Text] [Related]
17. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF. J Rheumatol Suppl; 1996 Mar 15; 44():72-4. PubMed ID: 8833058 [Abstract] [Full Text] [Related]
19. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group. J Rheumatol; 2003 Apr 15; 30(4):697-704. PubMed ID: 12672186 [Abstract] [Full Text] [Related]